The Biological Computing Company is one of the most commercially ambitious wetware companies, targeting the AI infrastructure market rather than clinical applications, with $25M seed funding suggesting strong investor conviction in biological computing as a complement to silicon. Its Algorithm Discovery platform is a differentiating concept, though its 10-to-20-year roadmap candidly reflects how early the underlying biology-AI integration remains.